Latest Germany News

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

EVT Limited posted strong FY26 growth across hotels and entertainment, unveiling a $800 million capital recycling program and a strategic group structure review to fuel future expansion.

WAM Global's FY2026 investment portfolio fell 4.2%, dragging the company to a $35.2 million net loss despite a 6.6 cent fully franked final dividend.

Hansen Technologies posted a modest 1.5% revenue dip to $386.5 million in FY26 but delivered a 15.9% rise in underlying NPATA to $65.9 million, driven by recurring revenue growth and AI-enabled efficiencies. The company also announced a planned CEO succession to support its next growth phase.

Impact Minerals (ASX:IPT) has initiated a renounceable pro-rata entitlement offer to raise up to $4.13 million at $0.032 per share, with two free attaching options for every three new shares. The partially underwritten raise aims to fund exploration and development across its key projects including High Purity Alumina.

Life360 has surged past 100 million monthly active users, posting record revenue and subscriber growth in Q2 2026. Its AI-driven platform and expanding advertising business underpin strong profitability and a confident outlook.

Percheron Therapeutics announces Dr Michael Baker as incoming CEO, replacing Dr James Garner who steps down after three years. Baker’s appointment aligns executive incentives with shareholder value as the company prepares for a pivotal HMBD-002 clinical trial.

Viking Mines has uncovered significant tungsten mineralisation in historical rock stockpiles at its Linka Tungsten Project, Nevada, with assay results reaching 1.8% WO3, well above the historical mined average. The findings open the door to potential ore sorting applications and advance the project towards a brownfields restart.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

GreenX Metals has expanded its Eleonore North Project with two new licences covering about 1,600 km² in East Greenland, targeting intrusion-related gold and critical minerals like tungsten. Historical data shows high gold grades up to 50 g/t, with fieldwork results due this quarter.

ClearVue Technologies has developed a unique manufacturing capability allowing its Gen 3 Vision Glass to have soft high-performance Low-E coatings applied on surface 4, the optimal position for solar heat control, after photovoltaic cells are laminated. This breakthrough enhances thermal performance and expands commercial façade market access globally.